Anna ladogana

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5986629/publications.pdf

Version: 2024-02-01

73 papers	5,031 citations	136950 32 h-index	91884 69 g-index
78 all docs	78 docs citations	78 times ranked	3781 citing authors

#	Article	IF	Citations
1	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. Brain, 2022, 145, 700-712.	7.6	16
2	Validation of Revised International Creutzfeldt-Jakob Disease Surveillance Network Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease. JAMA Network Open, 2022, 5, e2146319.	5.9	28
3	Phenotypic Heterogeneity of Variably Protease-Sensitive Prionopathy: A Report of Three Cases Carrying Different Genotypes at PRNP Codon 129. Viruses, 2022, 14, 367.	3.3	5
4	Prodynorphin and Proenkephalin in Cerebrospinal Fluid of Sporadic Creutzfeldtâ€“Jakob Disease. International Journal of Molecular Sciences, 2022, 23, 2051.	4.1	5
5	The Use of Real-Time Quaking-Induced Conversion for the Diagnosis of Human Prion Diseases. Frontiers in Aging Neuroscience, 2022, 14, 874734.	3.4	5
6	Concordance of <scp>CSF RTâ€QuIC</scp> across the European <scp>Creutzfeldtâ€Jakob</scp> Disease surveillance network. European Journal of Neurology, 2022, , .	3.3	7
7	Diagnostic and prognostic performance of CSF Î±â€synuclein in prion disease in the context of rapidly progressive dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12214.	2.4	8
8	Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurology, The, 2021, 20, 235-246.	10.2	151
9	TREM2 expression in the brain and biological fluids in prion diseases. Acta Neuropathologica, 2021, 141, 841-859.	7.7	18
10	The importance of ongoing international surveillance for Creutzfeldtâ€“Jakob disease. Nature Reviews Neurology, 2021, 17, 362-379.	10.1	69
11	Phenotypic diversity of genetic Creutzfeldtâ€“Jakob disease: a histo-molecular-based classification. Acta Neuropathologica, 2021, 142, 707-728.	7.7	24
12	Spatial Epidemiology of Sporadic Creutzfeldt-Jakob Disease in Apulia, Italy. Neuroepidemiology, 2020, 54, 83-90.	2.3	6
13	Ring trial of 2nd generation RTâ€QuIC diagnostic tests for sporadic CJD. Annals of Clinical and Translational Neurology, 2020, 7, 2262-2271.	3.7	27
14	Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1181-1188.	1.9	34
15	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	10.2	42
16	Genetic Creutzfeldt-Jakob disease in Sardinia: a case series linked to the PRNP R208H mutation due to a single founder effect. Neurogenetics, 2020, 21, 251-257.	1.4	4
17	Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease. Biomolecules, 2020, 10, 290.	4.0	10
18	Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathologica, 2020, 140, 49-62.	7.7	218

#	Article	IF	Citations
19	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Molecular Neurobiology, 2019, 56, 2811-2821.	4.0	20
20	Î±â€Synuclein RTâ€QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. Annals of Clinical and Translational Neurology, 2019, 6, 2120-2126.	3.7	87
21	Clinicopathological features of the rare form of Creutzfeldt-Jakob disease in R208H-V129V PRNP carrier. Acta Neuropathologica Communications, 2019, 7, 47.	5.2	3
22	Prion-related peripheral neuropathy in sporadic Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 424-427.	1.9	31
23	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's and Dementia, 2018, 14, 751-763.	0.8	61
24	Age at onset of genetic (E200K) and sporadic Creutzfeldt-Jakob diseases is modulated by the CYP4X1 gene. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1243-1249.	1.9	14
25	The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimer's Research and Therapy, 2018, 10, 3.	6.2	76
26	Genetic Creutzfeldtâ€“Jakob disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 219-242.	1.8	41
27	Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and AÎ²42 levels. Acta Neuropathologica, 2017, 133, 559-578.	7.7	129
28	Prion Strain Characterization of a Novel Subtype of Creutzfeldt-Jakob Disease. Journal of Virology, 2017, 91, .	3.4	14
29	Extended and direct evaluation of <scp>RT</scp>â€Qu<scp>IC</scp> assays for Creutzfeldtâ€Jakob disease diagnosis. Annals of Clinical and Translational Neurology, 2017, 4, 139-144.	3.7	79
30	Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples. JAMA Neurology, 2017, 74, 155.	9.0	176
31	Towards an early clinical diagnosis of sporadic CJD VV2 (ataxic type). Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 764-772.	1.9	33
32	Patient with rapidly evolving neurological disease with neuropathological lesions of Creutzfeldtâ€Jakob disease, Lewy body dementia, chronic subcortical vascular encephalopathy and meningothelial meningioma. Neuropathology, 2017, 37, 110-115.	1.2	5
33	Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings. Journal of Alzheimer's Disease, 2016, 50, 465-476.	2.6	65
34	Quantifying prion disease penetrance using large population control cohorts. Science Translational Medicine, 2016, 8, 322ra9.	12.4	289
35	Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. Molecular Neurobiology, 2016, 53, 2189-2199.	4.0	80
36	A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk. PLoS ONE, 2015, 10, e0123654.	2.5	28

#	Article	IF	Citations
37	Early-onset spastic paraparesis as presenting sign of familial Creutzfeldtâ€“Jakob disease. Parkinsonism and Related Disorders, 2015, 21, 1479-1480.	2.2	2
38	Rethinking of doxycycline therapy in Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 705-705.	1.9	10
39	The future for treating Creutzfeldtâ€“Jakob disease. Expert Opinion on Orphan Drugs, 2015, 3, 57-74.	0.8	11
40	Creutzfeldtâ€“Jakob disease masked by head trauma and features of Wilson's disease. International Journal of Neuroscience, 2015, 125, 312-314.	1.6	0
41	Mutant PrPCJD prevails over wild-type PrPCJD in the brain of V210I and R208H genetic Creutzfeldtâ€“Jakob disease patients. Biochemical and Biophysical Research Communications, 2014, 454, 289-294.	2.1	6
42	Age at Death of Creutzfeldt-Jakob Disease in Subsequent Family Generation Carrying the E200K Mutation of the Prion Protein Gene. PLoS ONE, 2013, 8, e60376.	2.5	11
43	Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD. Neurology, 2012, 79, 1012-1018.	1.1	7
44	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldtâ€“Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain, 2012, 135, 3051-3061.	7.6	135
45	Iatrogenic Creutzfeldt-Jakob Disease, Final Assessment. Emerging Infectious Diseases, 2012, 18, 901-907.	4.3	280
46	Transmission of sporadic Creutzfeldtâ€Jakob disease by blood transfusion: risk factor or possible biases. Transfusion, 2011, 51, 1556-1566.	1.6	51
47	Incidence and spectrum of sporadic Creutzfeldtâ€“Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathologica, 2009, 118, 659-671.	7.7	224
48	Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. Journal of Neurology, 2009, 256, 1620-1628.	3.6	77
49	Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain, 2009, 132, 2659-2668.	7.6	770
50	Creutzfeldt-Jakob disease: hopes for therapy. European Journal of Neurology, 2008, 15, 435-436.	3.3	8
51	CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. European Journal of Neurology, 2007, 14, 121-124.	3.3	61
52	Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. Journal of Neurology, 2007, 254, 901-906.	3.6	72
53	Genetic prion disease: the EUROCJD experience. Human Genetics, 2005, 118, 166-174.	3.8	391
54	Mortality from Human Transmissible Spongiform Encephalopathies: A Record Linkage Study. Neuroepidemiology, 2005, 24, 214-220.	2.3	4

#	Article	IF	Citations
55	Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain, 2004, 127, 2348-2359.	7.6	244
56	Mortality trend from sporadic Creutzfeldt-Jakob disease (CJD) in Italy, 1993â€“2000. Journal of Clinical Epidemiology, 2003, 56, 494-499.	5.0	21
57	Increased Brain Synthesis of Prostaglandin E₂and F₂-Isoprostane in Human and Experimental Transmissible Spongiform Encephalopathies. Journal of Neuropathology and Experimental Neurology, 2000, 59, 866-871.	1.7	96
58	Prion protein glycotype analysis in familial and sporadic Creutzfeldt-Jakob disease patients. Brain Research Bulletin, 1999, 49, 429-433.	3.0	36
59	Creutzfeldt-Jakob Disease Mortality in Italy, 1982â€“1996. Neuroepidemiology, 1999, 18, 92-100.	2.3	7
60	High incidence of Creutzfeldt-Jakob disease in rural Calabria, Italy. Lancet, The, 1998, 352, 1989-1990.	13.7	33
61	Recent Italian FFI Cases. Brain Pathology, 1998, 8, 564-566.	4.1	8
62	Effect of Amphotericin B on Different Experimental Strains of Spongiform Encephalopathy Agents. , 1996, , 271-281.		0
63	Proteinase-resistant protein in human neuroblastoma cells infected with brain material from Creutzfeldt-Jakob patient. Lancet, The, 1995, 345, 594-595.	13.7	46
64	Congo red prolongs the incubation period in scrapie-infected hamsters. Journal of Virology, 1995, 69, 506-508.	3.4	142
65	Immunodiagnosis of bovine spongiform encephalopathy. Livestock Science, 1994, 38, 41-46.	1.2	4
66	Alteration of potassium-evoked 5-HT release from virus-infected rat cortical synaptosomes. NeuroReport, 1993, 4, 555-558.	1.2	37
67	Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature, 1992, 356, 598-601.	27.8	166
68	Experimental drug treatment of scrapie: A pathogenetic basis for rationale therapeutics. European Journal of Epidemiology, 1991, 7, 556-561.	5.7	14
69	Measurement of the concentration of amphotericin B in brain tissue of scrapie-infected hamsters with a simple and sensitive method. Antimicrobial Agents and Chemotherapy, 1991, 35, 1486-1488.	3.2	12
70	Possible Implications of the Cellular Component of the Immune System in the Pathogenesis of Unconventional Slow Virus Infections. , 1990, , 135-149.		2
71	Amphotericin B: A Novel Class of Antiscrapie Drugs. Journal of Infectious Diseases, 1989, 160, 795-802.	4.0	53
72	Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie. Archives of Virology, 1989, 108, 145-149.	2.1	60

#	Article	IF	Citations
73	A retrospective study of Creutzfeldt-Jakob disease in Italy (1972?1986). European Journal of Epidemiology, 1988, 4, 482-487.	5.7	20